Stay updated on DARWINII Clinical Trial
Sign up to get notified when there's something new on the DARWINII Clinical Trial page.

Latest updates to the DARWINII Clinical Trial page
- Check8 days agoChange DetectedNew sections How to Read a Study Record, Common Questions, and How to Join a Study have been added to assist users in navigating and understanding the DARWINII study page. A recruitment status message now indicates no further participant enrollment, and the Interventional/Treatment label formatting was adjusted along with the introduction of a Revision: v3.6.0 note.SummaryDifference0.4%

- Check16 days agoChange DetectedThe revision label on the page has been updated from v3.5.4 to v3.5.5. This reflects a minor update to the site's revision history and does not change the study details or user-facing content.SummaryDifference0.0%

- Check22 days agoNo Change Detected
- Check37 days agoChange DetectedThe page footer revision was updated from v3.5.3 to v3.5.4, signaling a new version of the page or its underlying system. This change is a backend/content update and does not modify the displayed study information.SummaryDifference0.0%

- Check44 days agoChange DetectedDARWIN II's study status updated to Completed with primary completion and study completion dates now listed as 2025-11-30, while enrollment remains at 50. Drug labeling/details were clarified (Atezolizumab/MPDL3280A) and administrative items such as the IPD sharing plan and U.S. manufacturing notes were removed to reflect the finalized study record.SummaryDifference1%

- Check58 days agoChange DetectedThe page’s revision/version marker was updated from v3.5.2 to v3.5.3, indicating a site template or release update rather than a change to the study record content.SummaryDifference0.0%

- Check65 days agoChange DetectedPage version updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

Stay in the know with updates to DARWINII Clinical Trial
Enter your email address, and we'll notify you when there's something new on the DARWINII Clinical Trial page.